Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ocular Therapeutix, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.029 -- 00:00:04.914 Dr. Question and Answer session. To ask a question, please press star one. 00:00:04.914 -- 00:00:08.898 As a reminder, this conference call is being recorded and will be available for replay 00:00:08.898 -- 00:00:12.721 on the Investor Relations section of the Ocular Therapeutics website. 00:00:12.721 -- 00:00:16.965 I would now like to turn the call over to Ocular's Vice President of Investor Relations, 00:00:16.965 -- 00:00:20.088 Bill Slattery, Jr. Please go ahead, Mr. Slattery. 00:00:20.088 -- 00:00:23.945 Good morning, everyone, and thank you for joining us today. 00:00:23.945 -- 00:00:28.986 Earlier this morning, we issued a press release outlining our financial results and business 00:00:28.986 -- 00:00:32.196 updates for the third quarter 2024. 00:00:32.446 -- 00:00:37.747 Mindful of everyone's time, Ocular's Executive Chairman, President, and CEO, 00:00:37.747 -- 00:00:42.748 Dr. Praveen Dougal, will briefly provide a summary of recent business highlights 00:00:42.748 -- 00:00:45.669 so we can quickly get to your questions. 00:00:45.669 -- 00:00:51.110 Joining Dr. Dougal for the Q&A portion of the call will be Donald Notman, Chief Financial 00:00:51.110 -- 00:00:56.212 Officer and Chief Operating Officer Sanjay Nayak, Chief Strategy Officer, 00:00:56.212 -- 00:01:00.274 and Steve Myers, Chief Commercial Officer. 00:01:00.274 -- 00:01:05.637 We refer everyone to this morning's press release and our Form 10-Q for a comprehensive 00:01:05.637 -- 00:01:10.419 update of third quarter financial and business results. 00:01:10.640 -- 00:01:15.763 During today's call, certain statements we will be making constitute forward-looking 00:01:15.763 -- 00:01:20.966 statements under the safe harbor provisions of the Private Securities Lit...